No Data
No Data
Improved Revenues Required Before Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock's 27% Jump Looks Justified
Insiders At Aurinia Pharmaceuticals Sold US$2.0m In Stock, Alluding To Potential Weakness
Positive Outlook for Aurinia Pharmaceuticals Boosted by Favorable Lupus Nephritis Guidelines
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH) and Siemens Healthineers AG (OtherSEMHF)
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Express News | Aurinia Commends 2024 Updated Acr Guidelines for Screening, Treatment, and Management of Lupus Nephritis
No Data